UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
Not yet recruiting · NCT06933563 · Registry updated 2025-04-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Not yet recruiting | Early phase 1 | 2025-04-18 | NCT06933563 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Xiniao Biotech Co., Ltd. | 8 |
| Zhejiang University | 194 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The first affiliated hospital of medical college of zhejiang university | Hangzhou | China | 3 |